This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Satoh, F. Articles by Smith, D. M. Search for Related Content PubMed PubMed Citation Articles by Satoh, F. Articles by Smith, D. M.

Characterization of Human and Rat Glucagon-Like Peptide-1 Receptors in the Neurointermediate Lobe: Lack of Coupling to Either Stimulation or Inhibition of Adenylyl Cyclase¹

Endocrine Unit of the Department of Metabolic Medicine, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom W12 0NN; and Department of Histopathology, Ealing Hospital (M.F.), Southall, Middlesex, United Kingdom UB1 3HW

Address all correspondence and requests for reprints to: Dr. David M. Smith, Endocrine Unit of the Department of Metabolic Medicine, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom W12 0NN. E-mail: d.m.smith{at}ic.ac.uk

Glucagon-like peptide-1 (GLP-1) has been shown to bind to the posterior pituitary in the rat. We examined GLP-1 binding sites in human postmortem and rat pituitaries. Dense [¹²⁵I]GLP-1 binding was seen in both human and rat posterior pituitary. In rat neuroin-termediate lobe membranes the binding site showed a K_d of 0.2 ± 0.01 nM and a binding capacity of 600 ± 33 fmol/mg protein (n = 3). In human pituitary membranes the binding site showed a K_d of 0.82 ± 0.05 nM and a binding capacity of 680 ± 93 fmol/mg protein (n = 3). Chemical cross-linking showed a relative mol wt for the receptor-ligand complex of 73,100 ± 1,400 (n = 3) in man and 59,300 ± 900 (n = 3) in rat. GLP-1 (1 µM) failed to increase cAMP levels measured in rat neurointermediate lobes, whereas pituitary adenylate cyclase-activating polypeptide (100 nM) increased cAMP from a basal level of 14 ± 1 to 80 ± 4 pmol/neurointermediate lobe·15 min (n = 5; P < 0.01). GLP-1 (up to 1 µM) did not affect the pituitary adenylate cyclase-activating polypeptide-stimulated cAMP levels. GLP-1 (up to 1 µM) also did not stimulate release of vasopressin or oxytocin from isolated rat neurointermediate lobes. The posterior pituitary shows the highest density of GLP-1-binding sites yet seen, but their function and signal transduction mechanism remain unknown.

This article has been cited by other articles:

				M. Korner, M. Stockli, B. Waser, and J. C. Reubi GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting J. Nucl. Med., May 1, 2007; 48(5): 736 - 743. [Abstract] [Full Text] [PDF]

				K K Sidhu, R C Fowkes, R H Skelly, and J M Burrin Exogenous expression of glucagon-like peptide 1 receptor and human insulin in AtT-20 corticotrophs confers cAMP-mediated gene transcription and insulin secretion J. Endocrinol., December 1, 2005; 187(3): 419 - 427. [Abstract] [Full Text] [PDF]

				T. Perry, N. J. Haughey, M. P. Mattson, J. M. Egan, and N. H. Greig Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4 J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 881 - 888. [Abstract] [Full Text] [PDF]

				H. L. Ward, C. J. Small, K. G. Murphy, A. R. Kennedy, M. A. Ghatei, and S. R. Bloom The Actions of Tuberoinfundibular Peptide on the Hypothalamo-Pituitary Axes Endocrinology, August 1, 2001; 142(8): 3451 - 3456. [Abstract] [Full Text] [PDF]

				Y.-H. Choi and G. H. Anderson An Interaction between Hypothalamic Glucagon-Like Peptide-1 and Macronutrient Composition Determines Food Intake in Rats J. Nutr., June 1, 2001; 131(6): 1819 - 1825. [Abstract] [Full Text]